Severe vincristine-related neurotoxicity in 5 patients with pediatric acute lymphoblastic leukemia requiring discontinuation of vincristine: A description of long-term outcome Journal Article


Authors: Egan-Sherry, D.; Bhuta, R.; Cole, P. D.; Gennarini, L. M.; Kahn, J. M.; Sulis, M. L.; DeNardo, B. D.; Welch, J. J. G.
Article Title: Severe vincristine-related neurotoxicity in 5 patients with pediatric acute lymphoblastic leukemia requiring discontinuation of vincristine: A description of long-term outcome
Abstract: Vincristine, a key agent in the treatment of many pediatric malignancies, causes sensory, motor and autonomic neuropathy. We report the clinical courses of 5 patients who required cessation of vincristine after developing severe neurotoxicity during treatment for acute lymphoblastic leukemia. All 5 patients lost the ability to ambulate and 3 had additional severe neurotoxic side effects including vision loss and vocal cord dysfunction. Although prior literature reports poor outcomes for children in whom vincristine was discontinued during acute lymphoblastic leukemia therapy, all 5 patients described here achieved and have maintained complete continuous remission. © 2021 Lippincott Williams and Wilkins. All rights reserved.
Keywords: neurotoxicity; vincristine; acute lymphoblastic leukemia
Journal Title: Journal of Pediatric Hematology/Oncology
Volume: 43
Issue: 7
ISSN: 1077-4114
Publisher: Lippincott Williams & Wilkins  
Date Published: 2021-10-01
Start Page: e997
End Page: e999
Language: English
DOI: 10.1097/mph.0000000000002114
PUBMED: 34001785
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 2 November 2021 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Maria Luisa Sulis
    42 Sulis